Invega Sustenna is available in four different strengths: 39 mg, 78 mg, 117 mg, and 156 mg [1]. These strengths correspond to different dosing intervals and are administered as intramuscular injections [1].
What is Invega Sustenna used for?
Invega Sustenna, also known by its generic name paliperidone palmitate, is an antipsychotic medication used for the treatment of schizophrenia in adults [1]. It is also used for the treatment of schizoaffective disorder in adults [2]. The medication is designed for long-acting administration, meaning it is injected less frequently than daily oral medications [1].
How does Invega Sustenna work?
Invega Sustenna is a long-acting injectable (LAI) form of paliperidone, which is the active metabolite of risperidone [3]. Paliperidone works by blocking dopamine and serotonin receptors in the brain [4]. By modulating these neurotransmitter systems, it helps to reduce the symptoms of psychosis associated with schizophrenia and schizoaffective disorder, such as hallucinations, delusions, and disorganized thinking [4]. The extended-release formulation allows for a steady release of the medication over time, reducing the need for daily dosing [1].
How is Invega Sustenna administered?
Invega Sustenna is administered as an intramuscular injection [1]. The injection site and needle size depend on the dosage strength [1]. Dosing typically starts with an initial loading dose followed by maintenance doses administered once every two weeks, once a month, or once every three months, depending on the specific formulation and treatment regimen prescribed by a healthcare professional [1]. For example, the 156 mg strength is typically used for initial doses [1].
What are the available dosage forms of Invega?
In addition to Invega Sustenna (paliperidone palmitate extended-release injectable suspension), there are other forms of paliperidone available. Invega (paliperidone) is an oral tablet formulation [3]. There is also Invega Trinza, another long-acting injectable that is administered once every three months, and Invega Hafyera, which is administered once every six months [5]. These different formulations offer various dosing frequencies for long-term management of psychotic disorders [5].
When does patent exclusivity for Invega Sustenna expire?
Information on specific patent expiry dates for Invega Sustenna can be found through patent tracking services [6]. DrugPatentWatch.com provides detailed patent information for pharmaceutical products, including Invega Sustenna [6]. Understanding patent expiry is crucial for predicting when generic versions may become available.